Chinese health product marketer AiXin Life International has withdrawn its plan for an initial public offering (IPO) in the United States. The company initially filed for an IPO in 2023, aiming to raise $25 million. It later reduced the target to $7 million before revising it upward again to $10 million through the issuance of 2.5 million shares at $4 per share. AiXin Life International had planned to list on the Nasdaq under the ticker symbol "AIXN," with Boustead Securities acting as the sole underwriter for the offering.
Founded in 2001 and headquartered in Chengdu, China, the company reported revenue of $4 million for the twelve months ended September 30, 2024. More critically, as of April 2026, its trailing twelve-month net loss had reached approximately $2.86 million, with its gross margin in negative territory. The company has also faced compliance warnings in recent periods due to multiple failures to submit its annual financial reports on time.
While AiXin Life International's business extends beyond health product distribution to include diversification efforts such as hotel acquisitions, this strategy has not succeeded in reversing its financial decline. Following the withdrawal of its IPO application, the company will continue to operate in the over-the-counter market. Industry analysis suggests that AiXin Life's situation is not unique; it reflects common challenges faced by many small and mid-sized Chinese companies seeking U.S. listings, including issues related to financial transparency, rising compliance costs, and insufficient secondary market liquidity.
Comments